These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
288 related items for PubMed ID: 20638197
1. Triple-negative or HER2-positive status predicts higher rates of locoregional recurrence in node-positive breast cancer patients after mastectomy. Wang SL, Li YX, Song YW, Wang WH, Jin J, Liu YP, Liu XF, Yu ZH. Int J Radiat Oncol Biol Phys; 2011 Jul 15; 80(4):1095-101. PubMed ID: 20638197 [Abstract] [Full Text] [Related]
7. Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy. Margalit DN, Sreedhara M, Chen YH, Catalano PJ, Nguyen PL, Golshan M, Overmoyer BA, Harris JR, Brock JE. Ann Surg Oncol; 2013 Mar 15; 20(3):811-8. PubMed ID: 22956068 [Abstract] [Full Text] [Related]
9. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, Bellon JR, Wong JS, Smith BL, Harris JR. J Clin Oncol; 2008 May 10; 26(14):2373-8. PubMed ID: 18413639 [Abstract] [Full Text] [Related]
10. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence. Han K, Nofech-Mozes S, Narod S, Hanna W, Vesprini D, Saskin R, Taylor C, Kong I, Paszat L, Rakovitch E. Clin Oncol (R Coll Radiol); 2012 Apr 10; 24(3):183-9. PubMed ID: 21958729 [Abstract] [Full Text] [Related]
12. Predictive value of breast cancer molecular subtypes in Chinese patients with four or more positive nodes after postmastectomy radiotherapy. Wu SG, He ZY, Li Q, Li FY, Lin Q, Lin HX, Guan XX. Breast; 2012 Oct 10; 21(5):657-61. PubMed ID: 22835918 [Abstract] [Full Text] [Related]
13. Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. Buchholz TA, Huang EH, Berry D, Pusztai L, Strom EA, McNeese MD, Perkins GH, Schechter NR, Kuerer HM, Buzdar AU, Valero V, Hunt KK, Hortobagyi GN, Sahin AA. Int J Radiat Oncol Biol Phys; 2004 Aug 01; 59(5):1337-42. PubMed ID: 15275718 [Abstract] [Full Text] [Related]
14. Clinicopathologic significance of excision repair cross-complementation 1 expression in patients treated with breast-conserving surgery and radiation therapy. Goyal S, Parikh RR, Green C, Schiff D, Moran MS, Yang Q, Haffty BG. Int J Radiat Oncol Biol Phys; 2010 Mar 01; 76(3):679-84. PubMed ID: 19464815 [Abstract] [Full Text] [Related]
17. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer. Saha B, Zhang N, Naritoku WY, Tsao-Wei DD, Groshen SL, Carlsson G, Larsson L, Gustavsson B, Chaiwun B, Taylor CR, Imam SA. Anticancer Res; 2004 Mar 01; 24(4):2391-400. PubMed ID: 15330189 [Abstract] [Full Text] [Related]
18. Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004. Brown M, Bauer K, Pare M. Breast Cancer Res Treat; 2010 Feb 01; 120(1):217-27. PubMed ID: 19629680 [Abstract] [Full Text] [Related]
20. Is conservative surgery a good option for patients with "triple negative" breast cancer? Martinez-Ramos D, Escrig-Sos J, Torrella-Ramos A, Alcalde-Sanchez M, Salvador-Sanchis JL. Breast; 2012 Jun 01; 21(3):401-5. PubMed ID: 22579462 [Abstract] [Full Text] [Related] Page: [Next] [New Search]